Table 1 FoundationOne™ genomic testing identified three driver mutations, of which two were actionable with available drugs
| Therapeutic Implications | ||
|---|---|---|
| Genomic Alteration | FDA-approved therapies for ovarian cancer | FDA-approved therapies for other tumor types |
| KRAS | None | Trametinib |
| G12v | ||
| PIK3CA | None | Everolimus, temsirolimus |
| H1047R | ||
| TERT | None | None |
| Promoter 124 C > T | ||